open access

Vol 64, No 4 (2013)
Case report
Published online: 2013-09-04
Submitted: 2013-09-04
Accepted: 2013-09-04
Get Citation

Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene — case study of three women from one family

Katarzyna Nabrdalik, Agnieszka Strózik, Mariola Minkina-Pędras, Przemysława Jarosz-Chobot, Wojciech Młynarski, Władysław Grzeszczak, Janusz Gumprecht
DOI: 10.5603/EP.2013.0010
·
Endokrynologia Polska 2013;64(4):306-311.

open access

Vol 64, No 4 (2013)
Case report
Published online: 2013-09-04
Submitted: 2013-09-04
Accepted: 2013-09-04

Abstract

Lipodystrophies are a heterogeneous group of diseases affecting adipose tissue distribution. Familial partial lipodystrophy of the Dunnigantype (FPLD) is a rare autosomal, dominant disorder caused by missense mutations in lamin A/C (LMNA) gene where selectiveloss of subcutaneous adipose tissue from the limbs and trunk, and accumulation of fat in the neck and face, is usually associated witha variety of metabolic disorders including insulin resistance, diabetes mellitus, dyslipidemia, hepatic steatosis and high blood pressure.In this report we present clinical and molecular features of three Polish women with FLPD phenotype coming from one family (a motherand her two daughters). FPLD was recognised under the circumstances of diabetes treatment, where sequencing of LMNA gene revealedheterozygous R482W mutation. In order to be able to recognise monogenic diabetes associated with lipodystrophy, it is important to bevery precise in physical examination while diagnosing diabetes and to be aware of the necessity of performing genetic testing. Diabetesappropriatedifferential diagnosis is essential for the treatment strategy, anticipation of the disease progression, and determination of theprognosis. It is necessary for an individual mutation carrier to look carefully at the patient’s family.

Abstract

Lipodystrophies are a heterogeneous group of diseases affecting adipose tissue distribution. Familial partial lipodystrophy of the Dunnigantype (FPLD) is a rare autosomal, dominant disorder caused by missense mutations in lamin A/C (LMNA) gene where selectiveloss of subcutaneous adipose tissue from the limbs and trunk, and accumulation of fat in the neck and face, is usually associated witha variety of metabolic disorders including insulin resistance, diabetes mellitus, dyslipidemia, hepatic steatosis and high blood pressure.In this report we present clinical and molecular features of three Polish women with FLPD phenotype coming from one family (a motherand her two daughters). FPLD was recognised under the circumstances of diabetes treatment, where sequencing of LMNA gene revealedheterozygous R482W mutation. In order to be able to recognise monogenic diabetes associated with lipodystrophy, it is important to bevery precise in physical examination while diagnosing diabetes and to be aware of the necessity of performing genetic testing. Diabetesappropriatedifferential diagnosis is essential for the treatment strategy, anticipation of the disease progression, and determination of theprognosis. It is necessary for an individual mutation carrier to look carefully at the patient’s family.
Get Citation

Keywords

diabetes mellitus, familial partial lipodystrophy, laminopathy, LMNA gene

About this article
Title

Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene — case study of three women from one family

Journal

Endokrynologia Polska

Issue

Vol 64, No 4 (2013)

Pages

306-311

Published online

2013-09-04

DOI

10.5603/EP.2013.0010

Bibliographic record

Endokrynologia Polska 2013;64(4):306-311.

Keywords

diabetes mellitus
familial partial lipodystrophy
laminopathy
LMNA gene

Authors

Katarzyna Nabrdalik
Agnieszka Strózik
Mariola Minkina-Pędras
Przemysława Jarosz-Chobot
Wojciech Młynarski
Władysław Grzeszczak
Janusz Gumprecht

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl